Overview
Updated 14 Jul 2026
David Siegel, MD, is Chief, Myeloma Division, John Theurer Cancer Center. The public record shows 699 publications with 39,798 citations (h-index 83), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 22 companies.
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Multiple Myeloma Research and Treatments
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 289.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
Sponsor: Hackensack Meridian Health
InvestigatorNot, yet, recruitingNCT06987708 - A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Sponsor: GlaxoSmithKline
InvestigatorPhase 3RecruitingNCT06679101 - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Sponsor: K36 Therapeutics, Inc.
InvestigatorPhase 1RecruitingNCT05651932
Industry payments
Updated 14 Jul 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20254 payments
- Janssen Biotech, Inc.Program year20253 payments
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Jul 2026
179 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 6651: Characterizing the risk of infections with T-cell engagers in multiple myeloma.
AACR Annual Meeting
AACR2026Co-author - Evaluation of immune checkpoint inhibitors and concurrent radiation therapy for the treatment of extramedullary multiple myeloma.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited worksby citation count (OpenAlex)
- 01A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 02Antitumor Activity of Thalidomide in Refractory Multiple Myeloma2,591 citations1999
- 03Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma2,449 citations2021
- 04
- 05Initial genome sequencing and analysis of multiple myeloma1,440 citations2011
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
92 2nd St, Hackensack, NJ 07601
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- MD
PhD, New York University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →regionalcancercare.org ↗ - Internal medicine internship/residency
New York University/Bellevue Hospital Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →regionalcancercare.org ↗ - Fellowship
Hematology/Medical Oncology, Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →regionalcancercare.org ↗ - Board certified
Internal Medicine and Medical Oncology; board eligible, Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →regionalcancercare.org ↗
Editorial & leadership rolesjournal and society appointments
- Founding Director
Institute for Multiple Myeloma and Lymphoma (iMML), Hackensack Meridian Health Center for Discovery & Innovation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hmh-cdi.org ↗ - Member
Steering Committee, Multiple Myeloma Research Consortium (MMRC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →media.mycme.com ↗
Awards & honorshonors on the public record
- George H. Cook Honors Scholar (1979)
provisional, low-confidence; could not independently corroborate beyond the single bio source
1979provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →media.mycme.com ↗
Secondary affiliationsappointments beyond the home institution
- Clinical Professor of Medicine
New York University (NYU) Medical Center / NYU School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →managingmyeloma.com ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →regionalcancercare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Myeloma Crowd Radio podcast/video interview
John Theurer Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/david-siegel-md-25c3543a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/David-Siegel-15
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - X / Twitter
x.com/DavidSSiegelMD
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
Mentions by otherswhere others cite or feature them
- Facebook
facebook.com/JTCancerCenter/posts/dr-david-siegel-chief-of-multiple-myeloma-at-john-theurer-cancer-center-at-hacke/10154683407070583
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - LinkedIn
linkedin.com/posts/john-theurer-cancer-center_dr-david-siegel-is-the-chief-of-the-myeloma-activity-6928343133785100288-rARR
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Boston University
- 3,069
- publications
- 199
- h-index
- 5
- trials
Paul Richardson, MD
Harvard University
- 2,062
- publications
- 172
- h-index
- 17
- trials
S Rajkumar, MD
WinnMed
- 1,861
- publications
- 166
- h-index
- 11
- trials
Meletios Dimopoulos, MD
Korea University
- 2,990
- publications
- 159
- h-index
- 13
- trials